

# Ioana R Preston

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3055508/publications.pdf>

Version: 2024-02-01

55  
papers

3,201  
citations

257450

24  
h-index

175258

52  
g-index

70  
all docs

70  
docs citations

70  
times ranked

3391  
citing authors

#	ARTICLE	IF	CITATIONS
1	Risk stratification and medical therapy of pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2019, 53, 1801889.	6.7	614
2	Updated Treatment Algorithm of Pulmonary Arterial Hypertension. <i>Journal of the American College of Cardiology</i> , 2013, 62, D60-D72.	2.8	596
3	Statement on Pregnancy in Pulmonary Hypertension from the Pulmonary Vascular Research Institute. <i>Pulmonary Circulation</i> , 2015, 5, 435-465.	1.7	230
4	Sotatercept for the Treatment of Pulmonary Arterial Hypertension. <i>New England Journal of Medicine</i> , 2021, 384, 1204-1215.	27.0	224
5	Right heart catheterisation: best practice and pitfalls in pulmonary hypertension. <i>European Respiratory Review</i> , 2015, 24, 642-652.	7.1	147
6	Pulmonary Arterial Capacitance Is an Important Predictor of Mortality in Heart Failure With a Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2015, 3, 467-474.	4.1	134
7	Higher Estradiol and Lower Dehydroepiandrosterone-Sulfate Levels Are Associated with Pulmonary Arterial Hypertension in Men. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 193, 1168-1175.	5.6	104
8	Pulmonary Hemodynamic Responses to Brain Natriuretic Peptide and Sildenafil in Patients With Pulmonary Arterial Hypertension. <i>Chest</i> , 2006, 129, 417-425.	0.8	90
9	Role of 12-lipoxygenase in hypoxia-induced rat pulmonary artery smooth muscle cell proliferation. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2006, 290, L367-L374.	2.9	87
10	Inhaled Therapies for Pulmonary Hypertension. <i>Respiratory Care</i> , 2015, 60, 794-805.	1.6	80
11	Acute and chronic effects of sildenafil in patients with pulmonary arterial hypertension. <i>Respiratory Medicine</i> , 2005, 99, 1501-1510.	2.9	79
12	Mineralocorticoid receptor antagonism attenuates experimental pulmonary hypertension. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2013, 304, L678-L688.	2.9	79
13	Lower DHEA-S levels predict disease and worse outcomes in post-menopausal women with idiopathic, connective tissue disease- and congenital heart disease-associated pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2018, 51, 1800467.	6.7	54
14	Mechanism of Progressive Heart Failure and Significance of Pulmonary Hypertension in Obstructive Hypertrophic Cardiomyopathy. <i>Circulation: Heart Failure</i> , 2017, 10, e003689.	3.9	43
15	Levosimendan Improves Hemodynamics and Exercise Tolerance in PH-HFpEF. <i>JACC: Heart Failure</i> , 2021, 9, 360-370.	4.1	42
16	Transglutaminase 2 in pulmonary and cardiac tissue remodeling in experimental pulmonary hypertension. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2017, 313, L752-L762.	2.9	40
17	Synergistic Effects of ANP and Sildenafil on cGMP Levels and Amelioration of Acute Hypoxic Pulmonary Hypertension. <i>Experimental Biology and Medicine</i> , 2004, 229, 920-925.	2.4	38
18	Tissue transglutaminase promotes serotonin-induced AKT signaling and mitogenesis in pulmonary vascular smooth muscle cells. <i>Cellular Signalling</i> , 2014, 26, 2818-2825.	3.6	38

#	ARTICLE	IF	CITATIONS
19	Use of Selective Serotonin Reuptake Inhibitors and Outcomes in Pulmonary Arterial Hypertension. <i>Chest</i> , 2013, 144, 531-541.	0.8	37
20	Clinical Perspective of Hypoxia-Mediated Pulmonary Hypertension. <i>Antioxidants and Redox Signaling</i> , 2007, 9, 711-721.	5.4	35
21	An International Physician Survey of Chronic Thromboembolic Pulmonary Hypertension Management. <i>Pulmonary Circulation</i> , 2016, 6, 472-482.	1.7	33
22	Retinoids and Pulmonary Hypertension. <i>Circulation</i> , 2005, 111, 782-790.	1.6	31
23	Spironolactone-induced degradation of the TFIIH core complex XPB subunit suppresses NF- $\kappa$ B and AP-1 signalling. <i>Cardiovascular Research</i> , 2018, 114, 65-76.	3.8	27
24	Ambrisentan in portopulmonary hypertension: A multicenter, open-label trial. <i>Journal of Heart and Lung Transplantation</i> , 2020, 39, 464-472.	0.6	27
25	Results of an Expert Consensus Survey on the Treatment of Pulmonary Arterial Hypertension With Oral Prostacyclin Pathway Agents. <i>Chest</i> , 2020, 157, 955-965.	0.8	26
26	Comparison of Acute Hemodynamic Effects of Inhaled Nitric Oxide and Inhaled Epoprostenol in Patients with Pulmonary Hypertension. <i>Pulmonary Circulation</i> , 2013, 3, 68-73.	1.7	24
27	Screening Strategies for Pulmonary Hypertension in Patients With Interstitial Lung Disease. <i>Chest</i> , 2022, 162, 145-155.	0.8	24
28	Glycolysis regulated transglutaminase 2 activation in cardiopulmonary fibrogenic remodeling. <i>FASEB Journal</i> , 2020, 34, 930-944.	0.5	22
29	Plasma 12 $\omega$ - and 15 $\omega$ -Hydroxyeicosanoids are Predictors of Survival in Pulmonary Arterial Hypertension. <i>Pulmonary Circulation</i> , 2016, 6, 224-233.	1.7	21
30	Challenges in Pulmonary Hypertension: Controversies in Treating the Tip of the Iceberg. A Joint National Institutes of Health Clinical Center and Pulmonary Hypertension Association Symposium Report. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 166-174.	5.6	17
31	Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI <sub>2</sub> ) Receptor Agonist in Pulmonary Arterial Hypertension (GRIPHON) study. <i>Journal of Heart and Lung Transplantation</i> , 2018, 37, 401-408.	0.6	15
32	The Prognostic Significance of Pulmonary Arterial Capacitance in Pulmonary Arterial Hypertension: Single-Center Experience. <i>Pulmonary Circulation</i> , 2016, 6, 608-610.	1.7	14
33	New perspectives in long-term outcomes in clinical trials of pulmonary arterial hypertension. <i>European Respiratory Review</i> , 2013, 22, 495-502.	7.1	13
34	An International Physician Survey of Pulmonary Arterial Hypertension Management. <i>Pulmonary Circulation</i> , 2016, 6, 338-346.	1.7	13
35	Chronic Thromboembolic Pulmonary Hypertension: Experience from a Single Center in Mexico. <i>Lung</i> , 2016, 194, 315-323.	3.3	12
36	A Simple Derived Prediction Score for the Identification of an Elevated Pulmonary Artery Wedge Pressure Using Precatheterization Clinical Data in Patients Referred to a Pulmonary Hypertension Center. <i>Chest</i> , 2016, 149, 1261-1268.	0.8	12

#	ARTICLE	IF	CITATIONS
37	Safety and Efficacy of Transition from Inhaled Treprostinil to Parenteral Treprostinil in Selected Patients with Pulmonary Arterial Hypertension. <i>Pulmonary Circulation</i> , 2014, 4, 456-461.	1.7	11
38	Imatinib as Rescue Therapy in a Patient With Pulmonary Hypertension Associated With Gaucher Disease. <i>Chest</i> , 2014, 146, e81-e83.	0.8	10
39	Vitamin C Deficiency-Induced Pulmonary Arterial Hypertension. <i>Chest</i> , 2020, 157, e21-e23.	0.8	10
40	Alpha $\alpha$ -Catulin Co-localizes With Vimentin Intermediate Filaments and Functions in Pulmonary Vascular Endothelial Cell Migration via ROCK. <i>Journal of Cellular Physiology</i> , 2016, 231, 934-943.	4.1	8
41	Vascular cell-specific roles of mineralocorticoid receptors in pulmonary hypertension. <i>Pulmonary Circulation</i> , 2021, 11, 1-13.	1.7	8
42	Future Therapies in PAH: Update on the New Landscape and Drugs in the Pipeline. <i>Advances in Pulmonary Hypertension</i> , 2014, 13, 76-80.	0.1	7
43	Properly Diagnosing Pulmonary Arterial Hypertension. <i>American Journal of Cardiology</i> , 2013, 111, 2C-9C.	1.6	5
44	Effect of riociguat on pulmonary arterial compliance in the PATENT and CHEST studies. <i>Pulmonary Circulation</i> , 2020, 10, 204589402096383.	1.7	5
45	Efficacy and safety of riociguat in combination therapy for patients with pulmonary arterial hypertension (PATENT studies). <i>Pulmonary Circulation</i> , 2020, 10, 1-10.	1.7	4
46	Temporarily switching from oral to intravenous selexipag in patients with pulmonary arterial hypertension: safety, tolerability, and pharmacokinetic results from an open-label, phase III study. <i>Respiratory Research</i> , 2021, 22, 34.	3.6	3
47	Anti-coagulation in pulmonary arterial hypertension: the real blood and guts. <i>Journal of Thoracic Disease</i> , 2016, 8, E1106-E1107.	1.4	2
48	PH Grand Rounds: Pulmonary Artery Filling Defects: Are They All the Same?. <i>Advances in Pulmonary Hypertension</i> , 2014, 13, 122-124.	0.1	2
49	Pulmonary hypertension trials: how can we do better?. <i>Expert Review of Respiratory Medicine</i> , 2015, 9, 551-558.	2.5	1
50	Combination Therapies in Pulmonary Arterial Hypertension. <i>Advances in Pulmonary Hypertension</i> , 2008, 7, 235-242.	0.1	1
51	Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease: Diagnosis and Management. <i>Advances in Pulmonary Hypertension</i> , 2009, 8, 156-159.	0.1	1
52	Vascular smooth muscle ROCK1 contributes to hypoxia-induced pulmonary hypertension development in mice. <i>Biochemical and Biophysical Research Communications</i> , 2022, 604, 137-143.	2.1	1
53	Bridging the Science into Practice. <i>Pulmonary Circulation</i> , 2016, 6, 620-620.	1.7	0
54	Risk Stratification – What's My Risk? A Practitioner's Tool. <i>Advances in Pulmonary Hypertension</i> , 2019, 18, 84-86.	0.1	0

#	ARTICLE	IF	CITATIONS
55	General Supportive Care. Handbook of Experimental Pharmacology, 2013, 218, 153-160.	1.8	0